Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 0 3 Month Treasury Bond ETF (SGOV) vs 10X Genomics Inc (TXG) Price & Performance

iShares 0 3 Month Treasury Bond ETFTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares 0 3 Month Treasury Bond ETF vs 10X Genomics Inc — how do they compare? iShares 0 3 Month Treasury Bond ETF trades at $100.7, while 10X Genomics Inc trades at $47.48 (market cap $5.48B). The key difference: 10X Genomics Inc is trading nearer its 52-week high, iShares 0 3 Month Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.

SGOVTXG
Sector
Fixed IncomeHealth
52-Week High
$100.74$45.80
52-Week Low
$100.28$11.34
Market Cap
$5.48B
Enterprise Value
$5.02B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 0 3 Month Treasury Bond ETF

SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.59 with minimal daily movement, reflecting its stable nature as a short-term Treasury vehicle. Technical indicators show a bullish trend with strong moving average support, while oscillators remain neutral. The ETF continues to attract institutional interest as investors seek yield and stability amid rate uncertainty, with recent articles highlighting its role in cash management strategies.

SGOV offers investors a low-risk cash alternative with competitive yields around 3.5-3.6%, though its performance remains highly sensitive to Federal Reserve policy decisions. The primary risk involves potential rate hikes that could pressure short-term bond values, while the opportunity lies in providing liquidity and income in volatile markets.

10X Genomics Inc

TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.

The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares 0 3 Month Treasury Bond ETF

SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.

Read more on SGOV

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG